As of Apr 29
| -0.062 / -7.29%|
The 2 analysts offering 12-month price forecasts for Transition Therapeutics Inc have a median target of 2.58, with a high estimate of 4.09 and a low estimate of 1.08. The median estimate represents a +227.64% increase from the last price of 0.79.
The current consensus among 3 polled investment analysts is to Hold stock in Transition Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.